主要目的：评价注射用AK150治疗晚期恶性实体瘤的安全性和耐受性，评估剂量限制性毒性（DLT）的发生情况，确定最大耐受剂量（MTD）或未达到MTD情况下的最大给药剂量（MAD），并确定II期推荐剂量（RP2D）。次要目的：评价AK150在晚期恶性实体瘤试验参与者体内的药代动力学（PK）特征；评价AK150在晚期恶性实体瘤参与者体内的免疫原性；初步评估AK150在晚期恶性实体瘤中的抗肿瘤活性。探索性目的：探索参与者肿瘤组织中与研究药物抗肿瘤活性相关的潜在生物标志物；探索参与者外周血中细胞因子水平与药物安全性的关系；探索AK150在晚期恶性实体瘤参与者体内的药效动力学（PD）特征。

开始日期2026-05-15

申办/合作机构

中山康方生物医药有限公司

JPRN-jRCT2031250665

/ Recruiting临床3期

A phase III, multicenter, open trial to assess the efficacy and safety of NaPPS in people with knee-osteoarthritis

开始日期2026-01-01

申办/合作机构

ReqMed Co., Ltd.

NCT06917404

/ Recruiting临床3期

A Phase 3, Randomised, Double-Blind, Placebo-Controlled Multi-Centre Study to Evaluate the Treatment Effect of Pentosan Polysulfate Sodium Compared to Placebo in Participants With Knee Osteoarthritis Pain

The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.
Study details include:
* The study duration will be up to 64 weeks.
* The treatment duration will be 6 weeks.
* The visit frequency will be twice weekly during treatment.
* The visit/contact frequency will be every 4-6 weeks during the 52-week Follow-up period.
* Approximately 466 participants will be enrolled into this study.

开始日期2025-05-29

申办/合作机构

Paradigm Biopharmaceuticals Ltd.

100 项与木聚硫钠相关的临床结果

登录后查看更多信息

100 项与木聚硫钠相关的转化医学

登录后查看更多信息

100 项与木聚硫钠相关的专利（医药）

登录后查看更多信息

1,060

项与木聚硫钠相关的文献（医药）

2026-09-01·WATER RESEARCH

Enantioselective trophic transfer of chiral psychiatric pharmaceuticals in an effluent−impacted river food web

Article

作者: Wang, Weimin ; Cai, Zongwei ; Zhang, Hui ; Sun, Tao ; Chen, Guozhu ; Li, Lei ; Xie, Tian ; Cui, Baoshan

The enantiomeric signatures of chiral psychiatric pharmaceuticals (PPs) offer unique opportunities to trace their movement within food webs. However, the enantioselective trophic transfer of PPs in aquatic food webs remains poorly understood. Herein, the trophodynamics of 10 representative PPs, including 6 chiral pharmaceuticals and 4 achiral pharmaceuticals, were investigated in an effluent-impacted river food web in the Beiyun River, China. The median Σ₁₀PPs concentrations in aquatic organisms ranged from 11.6 ng/g dw (shrimp) to 352.7 ng/g dw (mussels). Diazepam (DIA) exhibited a biomagnification trend with a trophic magnification factor (TMF) of 1.28, whereas carbamazepine (CAR), sertraline (SER), citalopram (CIT), and fluoxetine (FLU) underwent trophic dilution, with TMFs ranging from 0.31 to 0.76. Enantiomeric fraction (EF) profiles across trophic levels (TLs) revealed significant enantioselective accumulation patterns for chiral PPs in aquatic species. The metabolic differences among aquatic organisms critically shaped the enantiomer signatures of chiral PPs in aquatic biota. The enantiomeric profiles of chiral PPs in lower-trophic-level biota were primarily governed by external exposure, whereas in vivo enantioselective metabolism became the predominant shaping factor in apex predators. This study highlights the role of species-specific metabolism in shaping the trophodynamics of chiral PPs in aquatic ecosystems, and underscores the necessity of incorporating enantiomeric perspective into environmental risk assessment for chiral compounds.

2026-08-01·ENVIRONMENTAL RESEARCH

Commercially important aquatic organisms as indicators of contamination, ecosystem health and human risks in one of the largest rivers of the Brazilian Equatorial Margin (Jaguaribe river, Ceará, Brazil)

Article

作者: Sousa, Lara I F ; Costa, Enzo M F ; Cavalcante, Rivelino M ; Caetano, Angélica L F ; Santos, Milena C M ; Teixeira, Iorrana J F B ; Lima, Asheley A S ; Lima, A Duciene F ; Lemos, Viviane A S ; Costa, Ana B ; Gonçalves, Larissa M ; Soares, Lara F ; Souza, Alessandro R S ; Silva, Pedro R C

Pollution is a major environmental stressor that threatens aquatic ecosystem integrity and the health of aquatic organisms. This study assessed contamination patterns, ecosystem health and human health risks linked to chronic contamination and bioaccumulation in the Jaguaribe River, Ceará, Brazil. Target compounds included PCBs, OCPs, PBDEs, and PPs, analyzed in sediments and in biota, crustaceans (Ucides cordatus), fish (Genidens barbus, Mugil curema, Lutjanus synagris) and mollusks (Crassostrea rhizophorae). Risk to human health was evaluated using HQ, THQ, and CR indices per USEPA guidelines. Fish showed the highest PCB concentrations (up to 42 ng/g, mainly PCB52 - reflecting contributions from diffuse urban sources and regional atmospheric deposition), while mollusks accumulated DDT metabolites (>20 ng/g). Crustaceans contained OCPs and pyrethroids (cypermethrin, deltamethrin). Sediments held heavier PCBs and residual pesticides like heptachlor and α-chlordane. All HQ and THQ values were below 1, and CR values remained within the USEPA "insignificant to acceptable" range (<10^-4), indicating no significant human health risk under the assessed exposure scenarios. Nevertheless, the widespread detection of legacy POPs and current-use pesticides highlights persistent, low-level exposure and ongoing contamination, underscoring the need for continuous monitoring, particularly for frequent consumers and vulnerable populations. Fish and crabs exhibited generally stable physiological condition, with minor variations likely associated with environmental stressors.

2026-08-01·FOOD RESEARCH INTERNATIONAL

Structural characteristics, modification, immunomodulation and anti-inflammatory of Polygonatum polysaccharides from three species: A comparative study

Review

作者: Lee, Zi Wai ; Zhu, Yiqing ; Li, Xiaojing ; Fan, Gongjian ; Yang, Xiaohu ; Zhou, Dandan ; Li, Tingting ; Wu, Caie

Polygonatum polysaccharides (PPs), derived from Polygonatum sibiricum, P. kingianum, and P. cyrtonema, have gained attention due to their important biological activities. However, differences in their structural characteristics lead to variations in physicochemical properties and functions. This review summarizes the main structural characteristics of PPs from the three species, including molecular weight, monosaccharide composition, and glycosidic linkages, and discusses their relationships with biological activities. Modification strategies, including physical, chemical, and biological approaches, are also discussed to illustrate how structure and function can be regulated. Overall, the biological activities of PPs are determined by the combined effects of multiple structural parameters, especially in immunomodulation and anti-inflammatory functions. However, challenges remain, including the lack of standardized analytical methods and limited understanding of precise structure-activity relationships. This review helps clarify the structure-activity relationships of PPs and points out key gaps for future research and application in functional foods.

项与木聚硫钠相关的新闻（医药）

2026-07-21

·PRNewswire

Parker Waichman LLP Comments on Growing Public Attention Surrounding GLP-1 Vision Loss Litigation

Growing litigation focuses on the alleged causal association between GLP-1 medications and non-arteritic anterior ischemic optic neuropathy (NAION). PORT WASHINGTON, N.Y., July 21, 2026 /PRNewswire/ -- Parker Waichman LLP today commented on the growing public attention surrounding litigation alleging that certain GLP-1 receptor agonist medications, including but not limited to Ozempic ®, Wegovy ®, Mounjaro ® and Zepbound®, may be associated with non-arteritic anterior ischemic optic neuropathy ("NAION"), a rare condition that can result in sudden and permanent vision loss. The litigation recently received additional attention following an investigative report by WSB-TV Channel 2 Action News, Atlanta's ABC affiliate, highlighting the allegations of a Georgia woman whose lawsuit is now part of the coordinated federal multidistrict litigation ("MDL") pending in the United States District Court for the Eastern District of Pennsylvania. The WSB-TV report is available here: Georgia woman part of lawsuit claiming link between GLP-1 weight-loss drugs and blindness. Parker Waichman Senior Litigation Counsel, Jason Goldstein, serves as Co-Chair of the Plaintiffs' Executive Committee, a leadership position appointed by the Court to help oversee the nationwide litigation. In that role, Mr. Goldstein works with other court-appointed counsel to coordinate discovery, develop scientific evidence, and advance claims on behalf of individuals alleging they suffered NAION after taking GLP-1 medications. "As more patients come forward with similar allegations, public awareness of this litigation continues to grow," said Goldstein. "Our focus remains on following the scientific evidence, conducting a thorough discovery process, and ensuring that individuals who allege they suffered devastating vision loss have the opportunity to pursue their claims." The litigation involves allegations concerning Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. Plaintiffs allege that the manufacturers failed to adequately warn physicians and patients of a potential risk of NAION. The manufacturers deny these allegations, and no court has determined that GLP-1 medications cause NAION. The lawsuits follow the publication of multiple peer-reviewed scientific studies evaluating a potential association between GLP-1 medications and NAION. As the litigation progresses, the parties are expected to present expert testimony and scientific evidence addressing issues of causation, product warnings, and regulatory compliance. Individuals who experienced sudden vision loss or who were diagnosed with NAION after taking a GLP-1 medication may wish to consult with an attorney regarding their legal rights. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. Specifically, the Firm is quite experienced in representing eye injury victims due to the negligence of pharmaceutical companies. Representative cases include In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Prod. Liab. Litig. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Jason Goldstein Phone: 516-466-6500 Email: [email protected] SOURCE Parker Waichman LLP 21% more press release views with Request a Demo

专利侵权

2026-07-01

·PRNewswire

Parker Waichman LLP Files Lawsuits on behalf of Georgia and California Residents Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic

Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo Nordisk's Ozempic. PORT WASHINGTON, N.Y., July 1, 2026 /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits on behalf of victims who were prescribed Ozempic or Wegovy and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. On June 29, 2026, the Firm filed a lawsuit on behalf of a Georgia resident who developed NAION after taking Ozempic and on June 30, 2026, the Firm filed a lawsuit on behalf of a California resident who developed NAION after taking Ozempic. See Precup v. Novo Nordisk Inc., et al. Docket No: 2:26-cv-04456 and Grant v. Novo Nordisk, Inc., et al. Docket No.: 2:26-cv-04521. Parker Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fights for Victims Nationwide "NAION is a devastating, and permanent, eye injury diagnosis. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic and Wegovy) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable." said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. Specifically, the Firm is quite experienced in representing eye injury victims due to the negligence of pharmaceutical companies. Representative cases include In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Prod. Liab. Litig. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Jason Goldstein Phone: 516-466-6500 Email: [email protected] SOURCE Parker Waichman LLP 21% more press release views with Request a Demo

专利侵权

2026-06-09

·PRNewswire

Parker Waichman LLP Files Lawsuit on behalf of Massachusetts Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy

Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleged that he or she developed NAION after taking Novo Nordisk's Wegovy. PORT WASHINGTON, N.Y., June 9, 2026 /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits on behalf of victims who were prescribed Ozempic or Wegovy and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. On June 5, 2026, the Firm filed a lawsuit on behalf of a Massachusetts resident who developed NAION after taking Wegovy. See Smith v. Novo Nordisk Inc., et al. Docket No: 2:26-cv-03872. Parker Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fights for Victims Nationwide "NAION is a devastating, and permanent, eye injury diagnosis. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic and Wegovy) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable." said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. Specifically, the Firm is quite experienced in representing eye injury victims due to the negligence of pharmaceutical companies. Representative cases include In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Prod. Liab. Litig. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Jason Goldstein Phone: 516-466-6500 Email: [email protected] SOURCE Parker Waichman LLP 21% more press release views with Request a Demo

专利侵权

100 项与木聚硫钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05428	木聚硫钠	C05BA04 G04BX15	DBSALT000991

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
间质性膀胱炎	美国	Janssen Pharmaceuticals, Inc.	1996-09-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	欧盟	Paradigm Biopharmaceuticals Ltd.	2022-03-18
骨关节炎	临床3期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
膀胱炎	临床3期	中国台湾	泰宗生物科技股份有限公司	2020-10-14
泌尿道感染	临床3期	中国台湾	泰宗生物科技股份有限公司	2020-10-14
黏多糖贮积症I型	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
黏多糖贮积症VI型	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
过敏性鼻炎	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
罗斯河热	临床2期	澳大利亚	Paradigm Biopharmaceuticals Ltd.	2022-01-30
季节性过敏性鼻炎	临床2期	瑞典	Paradigm Biopharmaceuticals Ltd.	2016-11-14
慢性前列腺炎	临床2期	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	2005-10-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DDW2026	N/A	腺瘤性结肠息肉病	10	Pentosan Polysulfate Sodium	廠淵鑰製糧範廠淵糧膚(獵壓願顧顧壓憲鑰廠獵) = 壓艱壓膚艱顧鹹夢顧選獵夢夢遞簾壓觸選觸廠 (憲鑰簾鏇鹹蓋築鏇壓積 ) 更多	积极	2026-05-02
2021 ARVO Annual Meeting (ARVO2021)	N/A	黄斑变性	-	Pentosan Polysulfate	蓋願鬱壓膚窪廠壓壓鏇(糧窪獵齋繭襯選蓋廠繭) = 憲獵壓壓蓋觸鏇齋繭憲鬱餘窪鹽憲廠艱鑰憲築 (鏇製蓋網襯壓鬱廠築襯, 238 ~ 290) 更多	不佳	2021-06-01
NCT02930005 (CTgov)	临床2期	躁郁症 \| 躁郁症1型 \| 分裂情感性障碍 ... 更多	8	Meclofenamic acid (Meclofenamic Acid)	顧簾繭夢鏇繭鬱糧夢襯 = 顧築獵獵範積膚鑰鹽範網積廠觸簾艱觸壓鑰簾 (憲鹹鹽網餘齋觸蓋廠鏇, 糧窪簾積遞襯鏇餘憲範 ~ 蓋築鑰蓋繭簾積築積鹽) 更多	-	2019-03-26
NCT02930005 (CTgov)	临床2期	躁郁症 \| 躁郁症1型 \| 分裂情感性障碍 ... 更多	8	Pentosan polysulfate sodium (Pentosan Polysulfate Sodium)	顧簾繭夢鏇繭鬱糧夢襯 = 網鏇鹹艱築齋鑰餘衊顧網積廠觸簾艱觸壓鑰簾 (憲鹹鹽網餘齋觸蓋廠鏇, 選製遞襯鑰範夢艱鹹鬱 ~ 獵網鬱窪鹽構齋衊窪網) 更多	-	2019-03-26
NCT00086684 (CTgov)	临床4期	间质性膀胱炎	369	Placebo	蓋膚齋鏇餘顧鹹糧醖憲 = 衊餘鏇願選鹹鬱繭廠鏇衊夢遞鏇製衊鹹鑰簾範 (願醖構窪鬱憲範淵範鑰, 構積願獵構鹽簾淵顧壓 ~ 願積鹽醖獵襯艱鬱繭簾) 更多	-	2012-07-06